GlobeNewswire

Server Technology's HDOT Rack Mount PDU Named a 2018 DCS Award Finalist For Alternating Phase Technology

Dela

Unique Product Innovation Receives Judge's Nod for Server Rack PDU Product of the Year

RENO, Nev., April 17, 2018 (GLOBE NEWSWIRE) -- Server Technology, a brand of Legrand and a leading provider of intelligent Rack Power Distribution Units a.k.a rack PDU(s), today announced that it has been selected as a finalist in the 2018 DCS Awards. Server Technology has been shortlisted in the Data Centre PDU Product of the Year category for their High Density Outlet Technology (HDOT) Rack PDUs with Alternating Phase outlet technology. Today's announcement marks the fifth year that Server Technology has been singled out for product excellence by the DCS Awards panel, winners are selected based solely on public votes received, with votingopen until 11 May.

The DCS Awards, in association with Datacentre Solutions magazine, are designed to reward the product designers, manufacturers, suppliers and providers operating in the data centre arena, recognising the achievements of the vendors and their business partners alike. Continually, DCS Awards judges have singled out Server Technology's server rack power strips as providing the industry with unique benefits above and beyond standard rack mount PDU solutions.

For the 2018 DCS Awards, Server Technology's patented Alternating Phase outlet technology on the High Density Outlet Technology (HDOT) PDUs stood out from among competitive offerings with its simplified load balancing and cable management for 3-Phase PDUs that distribute phased power on a per receptacle basis. This innovation provides tangible benefits in the form of shorter cable runs that result in better airflow, easier load balancing, and overall greater efficiencies.

"Providing Alternating Phase technology at the PDU level provides our customers with a highly customized power solution, specifically tailored to meet their individual needs. Testament to its success is the fact that HDOT is our fastest growing PDU in the market, doubling in quantity shipped year over year since 2014," said Travis Irons, Director of Engineering at Server Technology. "We are honored that our customized power solutions continue to be validated by technology professionals as among the best in the industry."

In addition to the 2018 finalist status, DCS Awards named the company:

  • 2017 "Individual of the Year" DCS Award for VP of International Sales, Marc Marazzi
  • 2016 "Data Centre PDU Product of the Year" DCS Award for HDOT
  • 2015 and 2014 "Data Centre Management Product of the Year" DCS Award for Sentry Power Manager (SPM)

Winners will be announced at a gala evening at the Grange, St Paul's Hotel, London on 24 May 2018.

For more information please contact lucy.holloway@servertech.com or visit www.servertech.com.

About Server Technology

Server Technology's power strategy experts are trusted to provide Rack PDU solutions for demanding data centers worldwide ranging from small technology startups to Fortune 100 powerhouses. Over 60,000 customers around the world rely on our rack power distribution units to increase density, facilitate capacity planning, improve power monitoring, and drive efficiency. Because power is all we do, you will find us in the best cloud and co-location providers, forward thinking labs and telecommunications operations. Server Technology customers consistently rank us as providing the highest quality PDU(s), the best customer support and most valuable innovation. Let us show you; we have over 12,000 PDU configurations to fit every data center need and 90% of our PDU(s) are shipped within 10 days. Only with Server Technology will customers Stay Powered, Be Supported and Get Ahead. www.servertech.com

About Legrand and Legrand, North and Central America

Legrand is a global specialist in electrical and digital building infrastructures. Its comprehensive offering of solutions for use in commercial, industrial, and residential markets makes it a benchmark for customers worldwide. Innovation for a steady flow of new products with high added value is a prime vector for growth, including, in particular, connected devices stemming from Legrand's global Eliot (Electricity and IoT) program. Legrand reported sales of $6.2 billion(USD) in 2017. Legrand has a strong presence in North and Central America, with a portfolio of well-known market brands and product lines that includes AFCO Systems, C2G, Cablofil, Chief, Da-Lite, Electrorack, Finelite, Luxul, Middle Atlantic Products, Milestone AV, Nuvo, OCL, On-Q, Ortronics, Pass & Seymour, Pinnacle, Projecta, QMotion, Quiktron, Raritan, Sanus, Server Technology, Solarfective, Vaddio, Vantage, Wattstopper, and Wiremold. Legrand is listed on Euronext Paris and is a component stock of indexes including the CAC40, FTSE4Good, MSCI World, ASPI, Corporate Oekom Rating, and DJSI (ISIN code FR0010307819). www.legrand.us

For more information, contact:
Betsey Rogers
Public Relations
BridgeView Marketing
1-603-821-0809
betsey@bridgeviewmarketing.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Server Technology via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum